Coley Pharmaceutical Group Receives Broad U.S. Patent

-- Issued patent expands Coley's proprietary franchise in CpG immune

stimulatory molecules --



Apr 05, 2001, 01:00 ET from Coley Pharmaceutical Group

    WELLESLEY, Mass., and LANGENFELD, Germany, April 5 /PRNewswire/ --
 Coley Pharmaceutical Group today announced that the U.S. Patent and Trademark
 Office has granted U.S. Patent No. 6,207,646 providing broad composition and
 use claims for CpG immune stimulants, a novel class of drugs that activate the
 immune system to treat disease.  The newly issued patent expands coverage for
 Coley's proprietary products in combination with antigens, whether the
 combination is conjugated or not, for the treatment of cancer, asthma, allergy
 and infectious diseases.
     "This patent, together with our three other issued U.S. patents, firmly
 establishes Coley's dominant intellectual property position for CpG immune
 stimulants and their therapeutic applications," said Robert L. Bratzler,
 Ph.D., Coley's President and Chief Executive Officer.  "We believe that our
 early, comprehensive patent coverage of CpG immune stimulants solidifies our
 leadership position in this field."  Dr. Bratzler further noted that Coley's
 intellectual property portfolio now includes 43 issued or pending U.S. patents
 and their foreign counterparts.
     This patent, entitled "Immunostimulatory Nucleic Acid Molecules," provides
 broad composition of matter claims, including oligonucleotide sequences and
 backbone modifications, for CpG immune stimulants in combination with
 antigens, and the use of these compounds to treat cancer, asthma, allergy and
 infectious diseases.  Inventors named on the patent include Arthur Krieg,
 M.D., Joel Kline, M.D., Dennis Klinman, M.D. and Alfred Steinberg, M.D.  Coley
 holds an exclusive worldwide license to this patent, which was issued to the
 University of Iowa Research Foundation, the U.S. Department of Health and
 Human Services and Coley Pharmaceutical Group.
     Coley Pharmaceutical Group is developing new CpG-based drugs for the
 treatment of cancer, asthma, allergy and infectious diseases and has nine
 clinical trials currently ongoing.  Coley's lead cancer product candidate,
 ProMune (TM) immune stimulant, can be used as a monotherapy or in multi-drug
 treatment regimens, and is in Phase I/II trials for non-Hodgkin's lymphoma,
 melanoma and basal cell carcinoma.  Coley expects to bring three additional
 products into clinical trials during the next 12 to 18 months.
     CpG immune stimulants are a novel class of molecules that activate the
 human immune system to fight disease.  Coley's products consist of proprietary
 synthetic oligonucleotide sequences that induce distinctly different immune
 response profiles, providing the potential to create highly specific
 therapies.  CpG products provide potent anticancer and anti-infective activity
 when used alone or in combination with disease-associated antigens, monoclonal
 antibodies or traditional drug therapies.  In addition, CpG products can
 "restore" allergic and asthmatic responses to more normal, non-symptomatic
 responses.
 
     About Coley Pharmaceutical Group
     Coley Pharmaceutical Group discovers, develops and commercializes CpG
 molecules, a novel class of drugs that activate the immune system to fight
 cancer, asthma, allergy and infectious diseases.  The company's lead product,
 ProMune (TM) immune stimulant, is in Phase I/II clinical trials for several
 cancer indications.  Coley currently has nine Phase I/II clinical trials
 ongoing, and has established a novel human cell screening discovery platform
 to rapidly validate new product candidates.  Coley is a private company with
 headquarters in the United States and additional operations in Germany and
 Canada.  For further information, please visit www.coleypharma.com.
 
     Contact:
     Patricia F. Dimond, Ph.D.
     Vice President, Corporate Communications & Strategic Development
     Coley Pharmaceutical Group
     +1.781.718.3616
     pdimond@coleypharma.com
 
     Sharon Karlsberg or
     Wendy Soutsos
     Ogilvy PR Worldwide (U.S.)
     +1.617.577.0006
     sharon.karlsberg@ogilvypr.com
 
     Michael Sinclair or
     Fay Weston
     Burns McClellan (Europe)
     +44 (0) 20.7665.6643
 
 

SOURCE Coley Pharmaceutical Group
    WELLESLEY, Mass., and LANGENFELD, Germany, April 5 /PRNewswire/ --
 Coley Pharmaceutical Group today announced that the U.S. Patent and Trademark
 Office has granted U.S. Patent No. 6,207,646 providing broad composition and
 use claims for CpG immune stimulants, a novel class of drugs that activate the
 immune system to treat disease.  The newly issued patent expands coverage for
 Coley's proprietary products in combination with antigens, whether the
 combination is conjugated or not, for the treatment of cancer, asthma, allergy
 and infectious diseases.
     "This patent, together with our three other issued U.S. patents, firmly
 establishes Coley's dominant intellectual property position for CpG immune
 stimulants and their therapeutic applications," said Robert L. Bratzler,
 Ph.D., Coley's President and Chief Executive Officer.  "We believe that our
 early, comprehensive patent coverage of CpG immune stimulants solidifies our
 leadership position in this field."  Dr. Bratzler further noted that Coley's
 intellectual property portfolio now includes 43 issued or pending U.S. patents
 and their foreign counterparts.
     This patent, entitled "Immunostimulatory Nucleic Acid Molecules," provides
 broad composition of matter claims, including oligonucleotide sequences and
 backbone modifications, for CpG immune stimulants in combination with
 antigens, and the use of these compounds to treat cancer, asthma, allergy and
 infectious diseases.  Inventors named on the patent include Arthur Krieg,
 M.D., Joel Kline, M.D., Dennis Klinman, M.D. and Alfred Steinberg, M.D.  Coley
 holds an exclusive worldwide license to this patent, which was issued to the
 University of Iowa Research Foundation, the U.S. Department of Health and
 Human Services and Coley Pharmaceutical Group.
     Coley Pharmaceutical Group is developing new CpG-based drugs for the
 treatment of cancer, asthma, allergy and infectious diseases and has nine
 clinical trials currently ongoing.  Coley's lead cancer product candidate,
 ProMune (TM) immune stimulant, can be used as a monotherapy or in multi-drug
 treatment regimens, and is in Phase I/II trials for non-Hodgkin's lymphoma,
 melanoma and basal cell carcinoma.  Coley expects to bring three additional
 products into clinical trials during the next 12 to 18 months.
     CpG immune stimulants are a novel class of molecules that activate the
 human immune system to fight disease.  Coley's products consist of proprietary
 synthetic oligonucleotide sequences that induce distinctly different immune
 response profiles, providing the potential to create highly specific
 therapies.  CpG products provide potent anticancer and anti-infective activity
 when used alone or in combination with disease-associated antigens, monoclonal
 antibodies or traditional drug therapies.  In addition, CpG products can
 "restore" allergic and asthmatic responses to more normal, non-symptomatic
 responses.
 
     About Coley Pharmaceutical Group
     Coley Pharmaceutical Group discovers, develops and commercializes CpG
 molecules, a novel class of drugs that activate the immune system to fight
 cancer, asthma, allergy and infectious diseases.  The company's lead product,
 ProMune (TM) immune stimulant, is in Phase I/II clinical trials for several
 cancer indications.  Coley currently has nine Phase I/II clinical trials
 ongoing, and has established a novel human cell screening discovery platform
 to rapidly validate new product candidates.  Coley is a private company with
 headquarters in the United States and additional operations in Germany and
 Canada.  For further information, please visit www.coleypharma.com.
 
     Contact:
     Patricia F. Dimond, Ph.D.
     Vice President, Corporate Communications & Strategic Development
     Coley Pharmaceutical Group
     +1.781.718.3616
     pdimond@coleypharma.com
 
     Sharon Karlsberg or
     Wendy Soutsos
     Ogilvy PR Worldwide (U.S.)
     +1.617.577.0006
     sharon.karlsberg@ogilvypr.com
 
     Michael Sinclair or
     Fay Weston
     Burns McClellan (Europe)
     +44 (0) 20.7665.6643
 
 SOURCE  Coley Pharmaceutical Group